All In Biotech

Drug Trial Radar · NCT07951762

A Phase I/II Clinical Trial of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in the Treatment of Advanced Solid Tumors.

An Open-label, Multicenter Phase I/II Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in Patients With Advanced Solid Tumors.

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

368

Planned (sponsor's estimate)

Start

Dec 30, 2026

Primary completion

Dec 30, 2028

Study completion Dec 30, 2029

Sponsor

Sponsor type
Industry
First posted
Nov 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter phase 1/2 clinical study to evaluate the efficacy and safety of SYS6043 monotherapy or SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • SYS6043+PD-1/VEGF bispecific antibodyDrug

    SYS6043: IV PD-1/VEGF bispecific antibody: IV

  • SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.Drug

    SYS6043: IV PD-1/VEGF bispecific antibody: IV Chemotherapy: cisplatin or carboplatin, IV

  • SYS6043 monotherapyDrug

    SYS6043: IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Incidences of AEsTime frame: From the signing of the informed consent form until 90 days after the last dose.
  2. Phase I: DLTTime frame: 21 days
  3. Phase I: MTD/RP2DTime frame: After phase I dose escalation stage. Approximately 4 months.
  4. Phase II: ORRTime frame: Up to 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.